B. Christopher Kim, Ph.D.
Dr. Kim is the Managing Partner of KSLSF and a Partner of Oxford Bioscience Partners. He is responsible for all aspects of investment, portfolio support and Fund operations of KSLSF. Dr. Kim’s investments include PharmAbcine (member of BOD, mAb therapies for cancer), Pathway Genomics (personalized genetic testing, San Diego), and CrystalGenomics (KOSDAQ listed, small molecules to treat inflammation, infection and cancer). Prior to KSLSF and OBP , Dr. Kim served as Associate Director and Head of Operations for the global BioMarker Development group at the Novartis Institutes for BioMedical Research. He held an additional role in corporate development and strategy while at Novartis. Previously, Dr. Kim was a member of the IBM Extreme Blue program, providing strategic direction for IBM HealthCare and Life Sciences . At Alkermes, he conducted preclinical pharmacology research to evaluate proprietary drug delivery systems. Throughout his career, Dr. Kim has been engaged by VC firms and biotech companies as their advisor or consultant. He is a Special Advisor of Extera Partners, a Cambridge-based investment bank specialized in life sciences transactions. Dr. Kim received an MBA from Carnegie Mellon University where he was President of the BioPharma Business Club. Dr. Kim obtained a Ph.D. in Biomedical Sciences from the University of Texas Health Science Center and the MD Anderson Cancer Center with a focus on developmental biology, and a BA in Economics and BS in Biology from the University of California at Irvine. Dr. Kim authored a number of peer-reviewed scientific publications in the areas of preclinical pharmacology, and developmental biology. E-mail
Jonathan J. Fleming
Mr. Fleming is a General Partner of KSLSF. He is also President and Treasurer of NEHI, a national health care policy think tank. Founded in 2002, NEHI is a nonprofit, non-partisan, evidence-based institute dedicated to identifying innovations that provide solutions to the most pressing issues facing our health care system today. Since 1999, Mr. Fleming has been the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, based in Boston, Massachusetts. Mr. Fleming has been in the investment business for more than 29 years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining Oxford Bioscience Partners in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage health care and biotechnology companies in Israel. Mr. Fleming is a director of Xencor (NASDAQ: XNCR) and several private early stage life science companies. He is also a director of Leerink Partners, a Boston based investment bank specializing in health care companies. In addition, Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2003, where he co-teaches a class on business strategy for life science managers. He is an advisor to the SBIR program of the National Cancer Institute. Mr. Fleming holds a Master’s degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs. E-mail
Robert Kamen, Ph.D.
Dr. Kamen has more than 30 years of managerial experience in the biotechnology industry. He was president of the Abbott Bioresearch Center and on Abbott Pharmaceutical’s Executive Management Committee, after serving as BASF Bioresearch Corporation’s president before its acquisition by Abbott. His organization was responsible for the discovery and manufacture of Humira, the anti-TNF monoclonal antibody which is now the world’s top selling drug. Earlier he led research at Genetics Institute, Inc, one of the pioneering biotech companies. He is now an Entrepreneur in Residence with Third Rock Ventures and also serves on several biopharmaceutical company boards and scientific advisory panels. Dr. Kamen graduated from Amherst College with an A.B. (summa cum laude) in biophysics. His doctoral studies at Harvard University in the laboratory of Prof. James D. Watson, resulted in a Ph.D. degree in biochemistry and molecular biology. After a post-doctoral fellowship at the University of Zürich, he moved to the Imperial Cancer Research Fund Laboratories, London, where he was head of its Transcription Laboratory. He is known for his fundamental contributions to the fields of gene expression, RNA stability, molecular virology, molecular oncology and human cytokines.
Brian Seed, Ph.D.
Brian Seed is a Professor of Genetics at Harvard Medical School and a member of the Center for Computational and Integrative Biology at Massachusetts General Hospital. His academic research has centered on the creation and exploitation of genetic selections that can be applied during the transient phase of expression of exogenous genes introduced into mammalian cells, as well as the study of signaling processes in the immune system. His recent interests lie in the identification of new approaches to therapeutic discovery for the creation of biologicals and small molecules that address societally important medical needs. Dr. Seed has been an advisor to large and small biopharmaceutical companies in the US and abroad for many years.